Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
12 Nov 2024
// BUSINESSWIRE
05 Nov 2024
// BUSINESSWIRE
13 Sep 2024
// BUSINESSWIRE
09 Sep 2024
// BUSINESSWIRE
09 Sep 2024
// BUSINESSWIRE
08 Aug 2024
// BUSINESSWIRE
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2024
Agenus Announces End-of-Phase-2 Meeting Outcomes for BOT/BAL in MSS Colorectal Cancer
Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 18, 2024
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
FDA Grants Agenus Type B Meeting for BOT/BAL Therapy in Colorectal Cancer
Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 16, 2024
Details:
Financing supports AGEN1181 and AGEN2034 Phase 3 for metastatic colorectal cancer without active liver metastases.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Ligand Pharmaceuticals
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 07, 2024
Lead Product(s) : Botensilimab,Balstilimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Ligand Pharmaceuticals
Deal Size : $100.0 million
Deal Type : Financing
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement
Details : Financing supports AGEN1181 and AGEN2034 Phase 3 for metastatic colorectal cancer without active liver metastases.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 07, 2024
Details:
AGEN1181 (botensilimab) is a novel innate/adaptive immune activator, a multifunctional Fc-enhanced anti-CTLA-4 with balstilimab (anti-PD-1) for metastatic microsatellite stable colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2024
Agenus Announces Updated Phase 1 Data On BOT/BAL in Colorectal Cancer
Details : AGEN1181 (botensilimab) is a novel innate/adaptive immune activator, a multifunctional Fc-enhanced anti-CTLA-4 with balstilimab (anti-PD-1) for metastatic microsatellite stable colorectal cancer.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 12, 2024
Details:
Under the agreement, Bristol licensed BMS-986442 (AGEN1777), a dual TIGIT and CD96 antagonist with an enhanced Fc region to improve tumor-reactive T cell responses, from Agenus and currently dosed first patient in the phase 2 of the ongoing clinical trial.
Lead Product(s): AGEN1777,Docetaxel,Nivolumab
Therapeutic Area: Oncology Brand Name: BMS-986442
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Bristol Myers Squibb
Deal Size: $1,560.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement December 11, 2023
Lead Product(s) : AGEN1777,Docetaxel,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $1,560.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Bristol licensed BMS-986442 (AGEN1777), a dual TIGIT and CD96 antagonist with an enhanced Fc region to improve tumor-reactive T cell responses, from Agenus and currently dosed first patient in the phase 2 of the ongoing clinical tria...
Brand Name : BMS-986442
Molecule Type : Large molecule
Upfront Cash : $200.0 million
December 11, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 10, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 23, 2023
Details:
AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds ctla-4 and has demonstrated activity in cancer patients. it has received fast track designation for colorectal cancer.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
Details : AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds ctla-4 and has demonstrated activity in cancer patients. it has received fast track designation for colorectal cancer.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 17, 2023
Details:
AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds CTLA-4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details : AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds CTLA-4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 28, 2023
Details:
AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Brand Name: AGEN1181
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.
Brand Name : AGEN1181
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 23, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?